CN Patent

CN106317035A — 恩格列净单晶及其制备方法和用途

Assigned to Waterstone Pharmaceuticals Wuhan Co Ltd · Expires 2017-01-11 · 9y expired

What this patent protects

本发明涉及一种恩格列净单晶及其制备方法和用途，其中，恩格列净的化学结构式如式I所示，所述恩格列净单晶的X射线粉末衍射在衍射角2θ有特征峰：13.33，14.66，18.81，20.33，23.44，26.84；所述恩格列净单晶的晶体结构为单斜晶系，空间群为C2，晶包内分子数Z＝4，常温下是无色片状结晶。该单晶的形态良好，纯度高达99％。

USPTO Abstract

本发明涉及一种恩格列净单晶及其制备方法和用途，其中，恩格列净的化学结构式如式I所示，所述恩格列净单晶的X射线粉末衍射在衍射角2θ有特征峰：13.33，14.66，18.81，20.33，23.44，26.84；所述恩格列净单晶的晶体结构为单斜晶系，空间群为C2，晶包内分子数Z＝4，常温下是无色片状结晶。该单晶的形态良好，纯度高达99％。

Drugs covered by this patent

Patent Metadata

Patent number
CN106317035A
Jurisdiction
CN
Classification
—
Expires
2017-01-11
Drug substance claim
No
Drug product claim
No
Assignee
Waterstone Pharmaceuticals Wuhan Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.